Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cleft Lip | 2 | 2023 | 7 | 1.530 |
Why?
|
| Cleft Palate | 2 | 2023 | 10 | 1.530 |
Why?
|
| Ischium | 1 | 2024 | 1 | 0.950 |
Why?
|
| Osteotomy | 1 | 2024 | 2 | 0.950 |
Why?
|
| Pressure Ulcer | 1 | 2024 | 6 | 0.940 |
Why?
|
| Orthopedics | 1 | 2023 | 1 | 0.920 |
Why?
|
| Drug Overdose | 1 | 2019 | 5 | 0.680 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 8 | 0.670 |
Why?
|
| Acetaminophen | 1 | 2019 | 18 | 0.670 |
Why?
|
| Infant | 3 | 2023 | 1446 | 0.390 |
Why?
|
| Humans | 6 | 2024 | 6896 | 0.360 |
Why?
|
| Calcium Channels | 3 | 2008 | 10 | 0.350 |
Why?
|
| Neurons | 3 | 2008 | 19 | 0.350 |
Why?
|
| Mushroom Bodies | 2 | 2007 | 2 | 0.330 |
Why?
|
| Male | 4 | 2024 | 3337 | 0.320 |
Why?
|
| Prospective Studies | 2 | 2019 | 525 | 0.280 |
Why?
|
| Calcium | 2 | 2007 | 41 | 0.270 |
Why?
|
| Spider Venoms | 1 | 2005 | 1 | 0.250 |
Why?
|
| Valine | 1 | 2005 | 2 | 0.250 |
Why?
|
| Adolescent | 2 | 2024 | 2197 | 0.250 |
Why?
|
| Ilium | 1 | 2024 | 2 | 0.240 |
Why?
|
| Spinal Fusion | 1 | 2024 | 3 | 0.240 |
Why?
|
| Scoliosis | 1 | 2024 | 6 | 0.240 |
Why?
|
| Surgical Instruments | 1 | 2023 | 5 | 0.230 |
Why?
|
| Nasal Septum | 1 | 2023 | 2 | 0.230 |
Why?
|
| Nose | 1 | 2023 | 7 | 0.230 |
Why?
|
| Cerebral Palsy | 1 | 2024 | 18 | 0.230 |
Why?
|
| Preoperative Care | 1 | 2023 | 26 | 0.230 |
Why?
|
| Child, Preschool | 2 | 2019 | 1569 | 0.230 |
Why?
|
| Child | 4 | 2022 | 3364 | 0.220 |
Why?
|
| Hypertension | 1 | 2022 | 66 | 0.200 |
Why?
|
| Rare Diseases | 1 | 2022 | 48 | 0.190 |
Why?
|
| Genomics | 1 | 2022 | 101 | 0.190 |
Why?
|
| Female | 3 | 2019 | 3525 | 0.190 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 196 | 0.170 |
Why?
|
| Half-Life | 1 | 2019 | 12 | 0.170 |
Why?
|
| Alanine Transaminase | 1 | 2019 | 10 | 0.170 |
Why?
|
| Child, Hospitalized | 1 | 2019 | 26 | 0.170 |
Why?
|
| Biomarkers | 1 | 2019 | 136 | 0.160 |
Why?
|
| Drosophila | 3 | 2008 | 7 | 0.160 |
Why?
|
| China | 1 | 2018 | 9 | 0.160 |
Why?
|
| Liver | 1 | 2019 | 126 | 0.160 |
Why?
|
| Treatment Outcome | 1 | 2018 | 622 | 0.130 |
Why?
|
| Retrospective Studies | 1 | 2018 | 1296 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2008 | 84 | 0.100 |
Why?
|
| Animals | 3 | 2008 | 729 | 0.080 |
Why?
|
| Patch-Clamp Techniques | 2 | 2008 | 2 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 2 | 2008 | 11 | 0.080 |
Why?
|
| Thapsigargin | 2 | 2007 | 3 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 21 | 0.080 |
Why?
|
| Calcium Channels, N-Type | 1 | 2008 | 2 | 0.080 |
Why?
|
| Synapses | 1 | 2008 | 2 | 0.080 |
Why?
|
| Parasympathetic Nervous System | 1 | 2008 | 2 | 0.080 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 2 | 0.080 |
Why?
|
| Action Potentials | 1 | 2008 | 5 | 0.080 |
Why?
|
| Drosophila Proteins | 1 | 2008 | 8 | 0.080 |
Why?
|
| Brain | 1 | 2008 | 80 | 0.080 |
Why?
|
| Neuronal Plasticity | 1 | 2007 | 2 | 0.080 |
Why?
|
| Calcium Signaling | 1 | 2007 | 4 | 0.080 |
Why?
|
| Receptors, Nicotinic | 1 | 2007 | 8 | 0.080 |
Why?
|
| Cobalt | 1 | 2005 | 1 | 0.060 |
Why?
|
| Curare | 1 | 2005 | 1 | 0.060 |
Why?
|
| Picrotoxin | 1 | 2005 | 1 | 0.060 |
Why?
|
| Pupa | 1 | 2005 | 1 | 0.060 |
Why?
|
| Tetrodotoxin | 1 | 2005 | 1 | 0.060 |
Why?
|
| Fura-2 | 1 | 2005 | 1 | 0.060 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2005 | 1 | 0.060 |
Why?
|
| Electric Stimulation | 1 | 2005 | 2 | 0.060 |
Why?
|
| Salicylates | 1 | 2005 | 2 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 2 | 0.060 |
Why?
|
| GABA Antagonists | 1 | 2005 | 2 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2005 | 6 | 0.060 |
Why?
|
| Chlorine | 1 | 2005 | 2 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2005 | 3 | 0.060 |
Why?
|
| Nicotinic Antagonists | 1 | 2005 | 8 | 0.060 |
Why?
|
| Caffeine | 1 | 2005 | 13 | 0.060 |
Why?
|
| Phenols | 1 | 2005 | 7 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2005 | 19 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2005 | 22 | 0.060 |
Why?
|
| Iodine | 1 | 2005 | 3 | 0.060 |
Why?
|
| Nicotine | 1 | 2005 | 10 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2005 | 32 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 16 | 0.060 |
Why?
|
| Age Factors | 1 | 2005 | 210 | 0.060 |
Why?
|
| Time Factors | 1 | 2005 | 250 | 0.060 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2022 | 19 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2022 | 26 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2022 | 67 | 0.050 |
Why?
|
| Genome | 1 | 2022 | 32 | 0.050 |
Why?
|
| Pedigree | 1 | 2022 | 59 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2022 | 115 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 99 | 0.050 |
Why?
|
| Adult | 1 | 2022 | 1181 | 0.040 |
Why?
|
| Sense Organs | 1 | 2008 | 1 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2008 | 1 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2008 | 5 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2008 | 6 | 0.020 |
Why?
|
| Neurotoxins | 1 | 2008 | 4 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 48 | 0.020 |
Why?
|
| Motor Activity | 1 | 2008 | 33 | 0.020 |
Why?
|
| Bungarotoxins | 1 | 2007 | 1 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2007 | 1 | 0.020 |
Why?
|
| Nicotinic Agonists | 1 | 2007 | 3 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2007 | 5 | 0.020 |
Why?
|